P
98.87
-2.81 (-2.76%)
| Previous Close | 101.68 |
| Open | 101.47 |
| Volume | 2,029,217 |
| Avg. Volume (3M) | 774,586 |
| Market Cap | 6,308,767,744 |
| Price / Earnings (Forward) | 24.33 |
| Price / Sales | 140.48 |
| Price / Book | 10.55 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Profit Margin | 27.04% |
| Operating Margin (TTM) | -68.18% |
| Diluted EPS (TTM) | 0.780 |
| Quarterly Revenue Growth (YOY) | -88.90% |
| Quarterly Earnings Growth (YOY) | 381.70% |
| Total Debt/Equity (MRQ) | 1.65% |
| Current Ratio (MRQ) | 17.25 |
| Operating Cash Flow (TTM) | 336.94 M |
| Levered Free Cash Flow (TTM) | 327.76 M |
| Return on Assets (TTM) | 2.48% |
| Return on Equity (TTM) | 8.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Protagonist Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.25 |
|
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.10% |
| % Held by Institutions | 108.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Johnson & Johnson | 31 Dec 2025 | 2,449,183 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 118.00 (Jefferies, 19.35%) | Buy |
| Median | 112.00 (13.28%) | |
| Low | 95.00 (Goldman Sachs, -3.91%) | Hold |
| Average | 109.29 (10.54%) | |
| Total | 6 Buy, 1 Hold | |
| Avg. Price @ Call | 86.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 03 Mar 2026 | 95.00 (-3.91%) | Hold | 91.30 |
| Barclays | 26 Feb 2026 | 113.00 (14.29%) | Buy | 88.39 |
| Citizens | 26 Feb 2026 | 112.00 (13.28%) | Buy | 88.39 |
| TD Cowen | 26 Feb 2026 | 100.00 (1.14%) | Buy | 88.39 |
| Jefferies | 02 Feb 2026 | 118.00 (19.35%) | Buy | 83.05 |
| HC Wainwright & Co. | 30 Jan 2026 | 117.00 (18.34%) | Buy | 81.80 |
| Truist Securities | 05 Jan 2026 | 110.00 (11.26%) | Buy | 84.18 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Mar 2026 | CNBC | FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi |
| 07 Jan 2026 | Announcement | Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 |
| 05 Jan 2026 | Announcement | Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |